Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vitro CRISPR-Cas9 correction of sickle cell disease and X-linked severe combined immunodeficiency mutations
NL-OMON43429Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2016
- Countries
- 1
01
Overview
Open-label trial in sickle cell disease (SCD) and X-linked severe combined immunodeficiency (X-SCID) (2 cohorts), sponsored by Amsterdam University Medical Center. Started May 2016; status: active, not recruiting.
02
Conditions
sickle cell disease (SCD)X-linked severe combined immunodeficiency (X-SCID)
Beyond the preview
Go deeper on NL-OMON43429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43429.